Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention
Rattachement africain : it. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Based on available data in the literature, current evidence supporting the analgesic role of antiresorptive drugs is weak. This study compared the efficacy of zoledronic acid (ZA) and denosumab (Dmab) in reducing bone pain and first Skeletal Related Events (SREs) in real world setting. METHODS: A retrospective observational cohort study was conducted in patients with female breast cancer-related bone metastases at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy, from January 2008 to January 2023. Patients were included if they had undergone at least 24 consecutive administrations of ZA or Dmab. The primary endpoint was the analgesic effect, evaluated in terms of average pain intensity, analgesic drug use (Word Health Organization analgesic ladder), and daily opioid doses (oral morphine equivalent, OME) assessed at 3, 6, 12, 18, and 24 months, analyzed by Bayesian longitudinal mixed-effects models. Secondary endpoints included first SREs and radiotherapy/surgery incidence. RESULTS: Among 364 patients (194 ZA, 170 Dmab), Dmab demonstrated a significant analgesic advantage. Dmab group showed an 89 % lower likelihood of increasing one analgesic ladder step, a mean reduction of 0.4 points on the numerical rating scale (95 % CI, -0.7, -0.1), and lower daily OME doses (0.77 mg vs. 6.2 mg for ZA). At 12 and 24 months, ZA and Dmab showed similar cumulative incidences of SREs and radiotherapy/surgery (p = 0.601 and p = 0.923). CONCLUSIONS: Dmab showed consistent superior effect than ZA in reducing bone pain in metastatic BC, yet both treatments delivered similar protection against SREs and the need for radiotherapy or surgery.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention
- Date Crossref
- 01/10/2025
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Fondazione IRCCS Istituto Nazionale dei Tumori pays non établi dans la noticeÉtablissement de santé
-
Sapienza University of Rome Department of Physiology and Pharmacology pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Sciences and Community Health Italy pays non établi dans la noticeÉtablissement de santé
-
Biostatistics for Clinical Research pays non établi dans la noticeÉtablissement de santé
-
Palliative Care pays non établi dans la noticeInstitution
-
Medical Oncology Department pays non établi dans la noticeInstitution
Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Physiology and Pharmacology — Sapienza University of Rome et Italy — Department of Clinical Sciences and Community Health, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.